Problems and Solutions in Laboratory Testing for Hemophilia

A diagnosis of hemophilia A or hemophilia B begins with clinical assessment of the patient and is facilitated by laboratory testing. The influence of the latter on a diagnosis of hemophilia A or hemophilia B is clear-a diagnosis cannot be made without laboratory confirmation of a deficiency of factor FVIII (FVIII) or factor IX (FIX), respectively. Moreover, the degree of hemophilia severity is specifically characterized by laboratory test results. In turn, patient management, including choice and application of therapies, is influenced by the diagnosis, as well as by identification of respective disease severity. An incorrect diagnosis may lead to inappropriate management and unnecessary therapy, and thus to adverse outcomes. Moreover, identification of factor inhibitors in hemophilia will lead to additional and differential treatments, and incorrect identification of inhibitors or inhibitor levels may also lead to inappropriate management. Problems in hemophilia diagnosis or inhibitor detection can occur at any stage in the clinical diagnosis/laboratory interface, from the "pre-preanalytical" to "preanalytical" to "analytical" to "postanalytical" to "post-postanalytical." This report outlines the various problems in laboratory testing for hemophilia and provides various strategies or solutions to overcome these challenges. Although some outlined solutions are specific to the potential errors related to hemophilia, others are general in nature and can be applied to other areas of laboratory hemostasis. Key to improvement in this area is adoption of best practice by all involved, including clinicians, phlebotomists, and laboratories. Also key is the recognition that such errors may occur, and thus that clinicians should assess laboratory test results in the context of their patient's clinical history and follow-up any potential errors, thus avoid misdiagnoses, by requesting repeat testing on a fresh sample.

[1]  L. Valentino,et al.  Towards personalizing haemophilia care: using the Haemophilia Severity Score to assess 178 patients in a single institution , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  M. Makris,et al.  Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A , 2013, Haematologica.

[3]  M. Franchini,et al.  Clinical Efficacy and Determinants of Response to Treatment with Desmopressin in Mild Hemophilia A , 2013, Seminars in Thrombosis & Hemostasis.

[4]  J. Oldenburg,et al.  Defining Severity of Hemophilia: More than Factor Levels , 2013, Seminars in Thrombosis & Hemostasis.

[5]  C. Santoro,et al.  Tailored versus Standard Dose Prophylaxis in Children with Hemophilia A , 2013, Seminars in Thrombosis & Hemostasis.

[6]  G. Lippi,et al.  Influence of residual platelet count on routine coagulation, factor VIII, and factor IX testing in postfreeze-thaw samples. , 2013, Seminars in thrombosis and hemostasis.

[7]  E. Santagostino,et al.  Hemophilia A and Hemophilia B: Different Types of Diseases? , 2013, Seminars in Thrombosis & Hemostasis.

[8]  G. Lippi,et al.  FEIBA versus NovoSeven in Hemophilia Patients with Inhibitors , 2013, Seminars in Thrombosis & Hemostasis.

[9]  Bin Zhang,et al.  Combined Deficiency of Coagulation Factors V and VIII: An Update , 2013, Seminars in Thrombosis & Hemostasis.

[10]  G. Lippi,et al.  The order of draw: myth or science? , 2013, Clinical chemistry and laboratory medicine.

[11]  P. Mannucci,et al.  Is haemophilia B less severe than haemophilia A? , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  G. Lippi,et al.  Incorrect order of draw could be mitigate the patient safety: a phlebotomy management case report , 2013, Biochemia medica.

[13]  J. Venitz,et al.  Monitoring rFVIII prophylaxis dosing using global haemostasis assays , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[14]  S. Kitchen,et al.  Investigation of a prolonged APTT. Different approaches taken by laboratories to achieve the same diagnosis , 2013, International journal of laboratory hematology.

[15]  Guy Young,et al.  Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. , 2013, Blood.

[16]  E. Duncan,et al.  Diagnostic Testing for Mild Hemophilia A in Patients with Discrepant One-Stage, Two-Stage, and Chromogenic Factor VIII:C Assays , 2013, Seminars in Thrombosis & Hemostasis.

[17]  G. Kershaw,et al.  Mixing Tests: Diagnostic Aides in the Investigation of Prolonged Prothrombin Times and Activated Partial Thromboplastin Times , 2013, Seminars in Thrombosis & Hemostasis.

[18]  E. Favaloro,et al.  External Quality Assessment of Factor VIII Inhibitor Assays , 2013, Seminars in Thrombosis & Hemostasis.

[19]  G. Lippi,et al.  Interference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia , 2012, Seminars in Thrombosis & Hemostasis.

[20]  K. Kavaklı,et al.  Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  A. Šimundić,et al.  Laboratory networking and sample quality: a still relevant issue for patient safety , 2012, Clinical chemistry and laboratory medicine.

[22]  G. Lippi,et al.  The new oral anticoagulants and the future of haemostasis laboratory testing , 2012, Biochemia medica.

[23]  C. Hayward,et al.  Laboratory Investigations for Bleeding Disorders , 2012, Seminars in Thrombosis & Hemostasis.

[24]  A. Griesmacher,et al.  Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests , 2012, Clinical chemistry and laboratory medicine.

[25]  K. Webert Acquired Hemophilia A , 2012, Seminars in Thrombosis & Hemostasis.

[26]  A. Goodeve,et al.  Quality in Molecular Biology Testing for Inherited Thrombophilia Disorders , 2012, Seminars in Thrombosis & Hemostasis.

[27]  B. Verbruggen,et al.  Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis , 2012, Seminars in Thrombosis & Hemostasis.

[28]  M. Franchini,et al.  Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia A , 2012, Seminars in Thrombosis & Hemostasis.

[29]  C. Négrier,et al.  Global haemostasis and point of care testing , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[30]  G. Lippi,et al.  Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing , 2012, Seminars in Thrombosis & Hemostasis.

[31]  G. Lippi,et al.  Quality Standards for Sample Collection in Coagulation Testing , 2012, Seminars in Thrombosis & Hemostasis.

[32]  G. Lippi,et al.  Patient Safety and Quality in Laboratory and Hemostasis Testing: A Renewed Loop? , 2012, Seminars in Thrombosis & Hemostasis.

[33]  G. Kershaw,et al.  Laboratory identification of factor inhibitors: an update , 2012, Pathology.

[34]  G. Lippi,et al.  Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT , 2012, Journal of Thrombosis and Thrombolysis.

[35]  L. Alberio,et al.  Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. , 2012, Thrombosis research.

[36]  G. Lippi,et al.  Primary blood tubes mixing: time for updated recommendations , 2012, Clinical chemistry and laboratory medicine.

[37]  O. Olsen,et al.  Vatreptacog Alfa from Conception to Clinical Proof of Concept , 2012, Seminars in Thrombosis & Hemostasis.

[38]  Giuseppe Lippi,et al.  Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis , 2012 .

[39]  G. Lippi,et al.  Laboratory testing of anticoagulants: the present and the future , 2011, Pathology.

[40]  B. Verbruggen,et al.  The factor VIII inhibitor assays can be standardized: results of a workshop , 2011, Journal of thrombosis and haemostasis : JTH.

[41]  Giuseppe Lippi,et al.  Suitability of a transport box for blood sample shipment over a long period. , 2011, Clinical biochemistry.

[42]  C. Ruan,et al.  Diagnosis and Management of von Willebrand Disease in China , 2011, Seminars in thrombosis and hemostasis.

[43]  E. Favaloro,et al.  von Willebrand Disease: Local Diagnosis and Management of a Globally Distributed Bleeding Disorder , 2011, Seminars in thrombosis and hemostasis.

[44]  M. Makris,et al.  The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies , 2011, International journal of laboratory hematology.

[45]  T. Lindahl,et al.  Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays , 2011, Journal of thrombosis and haemostasis : JTH.

[46]  G. Lippi,et al.  Coagulation update: what's new in hemostasis testing? , 2011, Thrombosis research.

[47]  M. Popovsky,et al.  Clinical Utility of Thromboelastography: One Size Does Not Fit All , 2010, Seminars in thrombosis and hemostasis.

[48]  E. Berntorp,et al.  Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective , 2010, Seminars in thrombosis and hemostasis.

[49]  G. Lippi,et al.  Acquired hemophilia in pediatrics: A systematic review , 2010, Pediatric blood & cancer.

[50]  C. Kluft,et al.  External quality assessment for thrombin generation tests: an exploration. , 2010, Seminars in thrombosis and hemostasis.

[51]  S. Kitchen,et al.  Quality Assurance and Quality Control of Thrombelastography and Rotational Thromboelastometry: The UK NEQAS for Blood Coagulation Experience , 2010, Seminars in thrombosis and hemostasis.

[52]  E. Favaloro,et al.  Quality in coagulation and haemostasis testing , 2010 .

[53]  G. Lippi,et al.  Problems in laboratory testing: hemophilia and beyond , 2010, Journal of thrombosis and haemostasis : JTH.

[54]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[55]  G. Lippi,et al.  Right or wrong sample received for coagulation testing? Tentative algorithms for detection of an incorrect type of sample , 2010, International journal of laboratory hematology.

[56]  E. Favaloro,et al.  Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[57]  B. Verbruggen,et al.  The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation , 2009, Seminars in thrombosis and hemostasis.

[58]  G. Kershaw,et al.  Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. , 2009, Seminars in thrombosis and hemostasis.

[59]  E. Duncan,et al.  Investigations from External Quality Assurance Programs Reveal a High Degree of Variation in the Laboratory Identification of Coagulation Factor Inhibitors , 2009, Seminars in thrombosis and hemostasis.

[60]  S. Kitchen,et al.  Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. , 2009, Seminars in thrombosis and hemostasis.

[61]  S. McRae,et al.  Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. , 2009, Seminars in thrombosis and hemostasis.

[62]  G. Lippi,et al.  Influence of temperature and time before centrifugation of specimens for routine coagulation testing , 2009, International journal of laboratory hematology.

[63]  F. Peyvandi,et al.  Rare bleeding disorders. , 2009, Seminars in thrombosis and hemostasis.

[64]  Cedric Hermans,et al.  Laboratory Diagnosis and Molecular Classification of von Willebrand Disease , 2009, Acta Haematologica.

[65]  F. Peyvandi,et al.  Combined Factor V and Factor VIII Deficiency. , 2009, Seminars in Thrombosis and Hemostasis.

[66]  Z. Berneman,et al.  Recessive von Willebrand Disease Type 2 Normandy: Variable Expression of Mild Hemophilia and VWD Type 1 , 2009, Acta Haematologica.

[67]  Mario Plebani,et al.  Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics , 2009, Clinical chemistry and laboratory medicine.

[68]  G. Lippi,et al.  One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[69]  G. Lippi,et al.  Activated Partial Thromboplastin Time: New Tricks for an Old Dogma , 2008, Seminars in thrombosis and hemostasis.

[70]  G. Lippi,et al.  Laboratory, clinical and therapeutic aspects of acquired hemophilia A. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[71]  W. V. van Heerde,et al.  Diagnosis of factor VIII deficiency , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[72]  M. Blombäck,et al.  Validation of a composite score for clinical severity of hemophilia , 2008, Journal of thrombosis and haemostasis : JTH.

[73]  E. Favaloro,et al.  Lower Limit of Assay Sensitivity: An Under-recognised and Significant Problem in von Willebrand Disease Identification and Classification , 2008, American Society for Clinical Laboratory Science.

[74]  G. Lippi,et al.  Dishomogeneous separation of citrated plasma in primary collection tubes for routine coagulation testing. , 2008, Blood Coagulation and Fibrinolysis.

[75]  G. Lippi,et al.  Quality improvement in laboratory medicine: extra-analytical issues. , 2008, Clinics in laboratory medicine.

[76]  H. Watson,et al.  Can We Predict Bleeding? , 2008, Seminars in Thrombosis and Hemostasis.

[77]  E. Duncan,et al.  Mis‐identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation , 2007, Pathology.

[78]  G. Lippi,et al.  Influence of primary sample mixing on routine coagulation testing. , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[79]  G. Lippi,et al.  Influence of the centrifuge time of primary plasma tubes on routine coagulation testing , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[80]  W. Nichols,et al.  External quality assurance in thrombosis and hemostasis: an international perspective. , 2007, Seminars in thrombosis and hemostasis.

[81]  E. Favaloro Standardization, regulation, quality assurance and emerging technologies in hemostasis: issues, controversies, benefits, and limitations. , 2007, Seminars in thrombosis and hemostasis.

[82]  G. Lippi,et al.  Quality and reliability of routine coagulation testing: can we trust that sample? , 2006, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[83]  G. Lippi,et al.  Influence of centrifuge temperature on routine coagulation testing. , 2006, Clinical chemistry.

[84]  M. Franchini,et al.  Acquired hemophilia A. , 2011, Advances in clinical chemistry.

[85]  E. Favaloro,et al.  Cross-laboratory audit of normal reference ranges and assessment of ABO blood group, gender and age on detected levels of plasma coagulation factors , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[86]  G. Lippi,et al.  Short-term venous stasis influences routine coagulation testing , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[87]  M. Makris,et al.  SSC/ISTH classification of hemophilia A: can hemophilia center laboratories achieve the new criteria? , 2004, Journal of thrombosis and haemostasis : JTH.

[88]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[89]  G. Lippi,et al.  Sensitivity of two commercial reagents for prothrombin time and activated partial thromboplastin time to isolate coagulation factor deficiencies , 1999 .

[90]  B. Mercier,et al.  The "Normandy" variant of von Willebrand disease: characterization of a point mutation in the von Willebrand factor gene. , 1991, Blood.